XLotus

XLotus is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative gene therapies for ophthalmic and rare diseases. The company leverages its proprietary adeno-associated virus (AAV) vector platform to design treatments that address genetic mutations and chronic ocular conditions. Its lead program, XL-001, is an AAV-based gene therapy targeting RPE65-mediated Leber Congenital Amaurosis, which has received IND approval and entered clinical trials. XLotus aims to provide transformative solutions for patients with vision-threatening diseases through advanced genetic engineering and translational medicine. The company is supported by prominent venture capital firms and focuses on high-efficiency vector delivery systems.